{"id":514,"date":"2024-05-19T20:57:36","date_gmt":"2024-05-19T20:57:36","guid":{"rendered":"https:\/\/www.om2020vision.com\/?page_id=514"},"modified":"2024-05-26T16:50:10","modified_gmt":"2024-05-26T16:50:10","slug":"alpharet-2rt","status":"publish","type":"page","link":"https:\/\/www.om2020vision.com\/en\/alpharet-2rt\/","title":{"rendered":"AlphaRET 2RT"},"content":{"rendered":"<h2 class=\"screen-subtitle\" style=\"box-sizing: border-box; border-radius: 0px; font-family: &quot;Open Sans&quot;, Arial, sans-serif; font-weight: normal; line-height: 33px; color: rgb(85, 85, 85); font-size: 20px; text-shadow: none; text-transform: uppercase;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">RETINA REJUVENATION \u2013 NATURALLY<\/font><\/h2><p>&nbsp;<\/p><p>2RT\u2122 (Retinal Rejuvenation Therapy) is a proprietary, patented laser therapy that stimulates the eye&#039;s natural healing response to treat degenerative retinal diseases, including early stages of AMD. 2RT\u2122 features proprietary Nanopix\u2122 technology, which pairs a nanosecond laser pulse with a unique pixelated beam profile to exclusively target select single cells within the retinal pigment epithelium.<\/p>\n<h2 class=\"callout-title\" style=\"box-sizing: border-box; border-radius: 0px; font-family: &quot;Open Sans&quot;, Arial, sans-serif; font-weight: normal; line-height: 27px; color: rgb(85, 85, 85); margin-top: 5px; margin-bottom: 10px; font-size: 20px; text-shadow: none;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">Clinically proven to delay AMD<\/font><\/h2><p>The Laser Intervention in Early AMD (LEAD) clinical trial, a large randomized, controlled clinical trial, demonstrated the potential of 2RT\u2122 to significantly reduce the rate of disease progression in a specific group of patients with intermediate AMD.&nbsp;<span style=\"box-sizing: border-box; border-radius: 0px; position: relative; font-size: 9.75px; line-height: 0; vertical-align: baseline; top: -0.5em;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">1<\/font><\/span><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">&nbsp;&nbsp;Specifically, post hoc analyzes demonstrated that in patients who did not have coexisting reticular pseudodrusen (RPD), a fatty deposit associated with later stages of AMD (76% of enrolled patients), treatment with 2RT\u2122 produced a clinically significant result 77 Percentage reduction in the rate of disease progression.<\/font><\/p>\n<p><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\"><\/font><\/p><h3 class=\"callout-title\" style=\"box-sizing: border-box; border-radius: 0px; font-family: &quot;Open Sans&quot;, Arial, sans-serif; font-weight: normal; line-height: 27px; color: rgb(85, 85, 85); margin-top: 5px; margin-bottom: 10px; font-size: 20px; text-shadow: none;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">AMD \u2013 previous post<\/font><\/h3><p>2RT\u2122 offers the possibility of intervening early in the pathological process to improve retinal function and therefore slow down the degenerative processes associated with AMD in its early stages. Clinical and scientific studies demonstrate that 2RT\u2122 can induce a mononuclear cell response in the early intervention of AMD, including stimulation of microglia.&nbsp;<span style=\"box-sizing: border-box; border-radius: 0px; position: relative; font-size: 9.75px; line-height: 0; vertical-align: baseline; top: -0.5em;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">1,2<\/font><\/span><\/p>\n<p><span style=\"box-sizing: border-box; border-radius: 0px; position: relative; font-size: 9.75px; line-height: 0; vertical-align: baseline; top: -0.5em;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\"><\/font><\/span><\/p><h3 data-children-count=\"0\" style=\"box-sizing: border-box; border-radius: 0px; font-family: &quot;Open Sans&quot;, Arial, sans-serif; font-weight: normal; line-height: 27px; color: rgb(85, 85, 85); margin-top: 5px; margin-bottom: 10px; font-size: 20px; text-shadow: none;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">CSME \u2013 thermal damage avoided<\/font><\/h3><p>Unlike conventional retinal photocoagulation, which can cause permanent damage to sensitive structures in the eye, 2RT\u2122&nbsp;<span style=\"box-sizing: border-box; border-radius: 0px; position: relative; font-size: 9.75px; line-height: 0; vertical-align: baseline; top: -0.5em;\">&nbsp;<\/span><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">uses 500 times less energy than retinal photocoagulation and eliminates the incidence of thermal damage to the retina and surrounding cells in the effective treatment of clinically significant macular edema (CSME).&nbsp;<\/font><span style=\"box-sizing: border-box; border-radius: 0px; position: relative; font-size: 9.75px; line-height: 0; vertical-align: baseline; top: -0.5em;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">3<\/font><\/span><\/p>\n<p><span style=\"box-sizing: border-box; border-radius: 0px; position: relative; font-size: 9.75px; line-height: 0; vertical-align: baseline; top: -0.5em;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\"><\/font><\/span><\/p><h6 data-children-count=\"0\" style=\"box-sizing: border-box; border-radius: 0px; font-family: &quot;Open Sans&quot;, Arial, sans-serif; font-weight: normal; line-height: 18px; color: rgb(85, 85, 85); margin-top: 5px; margin-bottom: 10px; font-size: 12px; text-shadow: none;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">References:<\/font><\/h6><h6 class=\"small\" data-children-count=\"0\" style=\"box-sizing: border-box; border-radius: 0px; font-family: &quot;Open Sans&quot;, Arial, sans-serif; font-weight: normal; line-height: 18px; color: rgb(85, 85, 85); margin-top: 5px; margin-bottom: 10px; font-size: 11.05px; text-shadow: none;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">1. Jobling et al., \u201cNanosecond Laser Therapy Reverses Pathological and Molecular Changes in Age-Related Macular Degeneration Without Retinal Damage,\u201d The FASEB Journal 29, no. 2 (February 1, 2015): 696\u2013710, doi:10.1096\/fj.14-262444.<\/font><\/h6><h6 class=\"small\" data-children-count=\"0\" style=\"box-sizing: border-box; border-radius: 0px; font-family: &quot;Open Sans&quot;, Arial, sans-serif; font-weight: normal; line-height: 18px; color: rgb(85, 85, 85); margin-top: 5px; margin-bottom: 10px; font-size: 11.05px; text-shadow: none;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">2. Guymer, R.H., et al., Application of nanosecond laser in intermediate AMD: 12-month outcomes of fundus appearance and macular function. Clin Experiment Ophthalmol. 3 October 2013 doi: 10.1111\/ceo.12247.<\/font><\/h6><h6 class=\"small\" data-children-count=\"0\" style=\"box-sizing: border-box; border-radius: 0px; font-family: &quot;Open Sans&quot;, Arial, sans-serif; font-weight: normal; line-height: 18px; color: rgb(85, 85, 85); margin-top: 5px; margin-bottom: 10px; font-size: 11.05px; text-shadow: none;\"><font style=\"box-sizing: border-box; border-radius: 0px; vertical-align: inherit;\">3. Casson RJ. et al., \u201cRandomized pilot trial of a nanopulsed retinal laser versus conventional photocoagulation for the treatment of diabetic macular edema,\u201d Clin Experiment Ophthalmol. 2012 August;40(6):604-10<\/font><\/h6>","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"pagelayer_contact_templates":[],"_pagelayer_content":"","footnotes":""},"class_list":["post-514","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/www.om2020vision.com\/en\/wp-json\/wp\/v2\/pages\/514","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.om2020vision.com\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.om2020vision.com\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.om2020vision.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.om2020vision.com\/en\/wp-json\/wp\/v2\/comments?post=514"}],"version-history":[{"count":5,"href":"https:\/\/www.om2020vision.com\/en\/wp-json\/wp\/v2\/pages\/514\/revisions"}],"predecessor-version":[{"id":630,"href":"https:\/\/www.om2020vision.com\/en\/wp-json\/wp\/v2\/pages\/514\/revisions\/630"}],"wp:attachment":[{"href":"https:\/\/www.om2020vision.com\/en\/wp-json\/wp\/v2\/media?parent=514"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}